Prospectus & CPR14 Sep 2018 13:57
Sorry to bring up Ineos and the book again but it is germane regarding the Rights Issue (RI). “In our early days, commodity chemicals (mostly petrochemicals) were generically unpopular in the public markets because of their cyclicality and the analysts’ inability to forecast quarterly results. Which meant they (analysts) didn’t look good! In reality, commodity chemicals give a good return over the cycle. But sometimes you have to wait a bit.”
They were buying unfashionable businesses and eventually swallowed a whale. That was Innovene from BP for $9 billion (2005). That included Grangemouth , (Enquest Magnus with SVT as an add on?). They went partly blind into this deal. The Grangemouth was added late “We were now all of a sudden buying two huge refineries, and we knew f*** all about refineries”. If that wasn’t enough everything had to be done in total secrecy and within two months. The reason was that BP were in parallel negotiating an MBO with existing Innovene Directors. In fact Jim Ratcliffe didn’t meet Lord Browne until 10 years later. The confidentiality clause meant that normal due diligence was close to impossible. However, because of the MBO a lot of information was available due to prospectus and other necessary legal documents which they used instead. This brings me to the EnQuest RI which has given us a lot more granularity because of the prospectus and CPR on Magnus. It also gave me a lot of confidence because what I suspected was true (austerity) and only immediate and necessary maintenance was done until Kraken was producing (priorities). Through all this the company was under pressure from creditors. Some understanding, others not. It also never brought new problems to light despite Fernan's best efforts!
The dichotomy between bankers and industrialists is obvious and luckily there are individuals who can see it from both sides otherwise it would be stalemate. There are risks on both sides but the larger risk is always taken by the company and shareholders. Barclays’ analyst comes to his/her conclusion in the same way that Fernan does. It doesn’t make either wrong but I’d be surprised to see an analyst suddenly give a target of £1 for EnQuest presently. An analyst is a realist and has to be pragmatic. Their job depends on it and I remind you of the old stock market adage.
‘You can be right conventionally
You can be wrong unconventionally
You can be right unconventionally
You cannot be wrong unconventionally.’
Or ‘nobody ever got sacked for buying IBM’
However, I’ve found that past performance isn’t always a good guide for the future. Those of a lower risk tolerance should perhaps think twice before investing in EnQuest.